Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients

M. V. Fleming, Jr Guinee D.G., W. S. Chu, A. N. Freedman, N. E. Caporaso, W. P. Bennett, T. V. Colby, H. Tazelaar, S. L. Abbondanzo, J. Jett, P. Pairolero, V. Trastek, L. A. Liotta, C. C. Harris, W. D. Travis

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The bcl-2 gene is implicated in oncogenesis by its ability to prolong cell survival through the inhibition of apoptosis, without increasing cell proliferation. An association between immunohistochemical staining for bcl-2 protein and the histological type and prognosis of non-small cell carcinoma was hypothesized by Pezzella et al. (N Engl J Med 329:690-694, 1993). In a case series, we stained formalin-fixed, paraffin-bedded tumor tissue from 106 surgical non-small cell lung cancer patients with an antibody to bcl-2 protein (DAKO clone 124, Carpinteria, CA). The resulting bcl-2 staining data were evaluated for associations with demographic, histological, immunohistochemical, and genetic features, including p53 mutations. Bcl-2 staining was observed in tumors from 29 of 106 (27%) of subjects, but was significantly less frequent in subjects' adenocarcinoma histology (8 of 55, 14.6%) (P = .007). This finding persisted after adjustment for age, gender, stage, grade, smoking history, and disease-free survival. In univariate analyses, no association was seen with age, weight, body mass index, gender, or pack-years smoking; tumor grade, stage, or patient performance status; p53 or c-erbB2 immunohistochemical staining, or p53 mutations. These data agree with earlier reports that bcl-2 staining is less common in adenocarcinomas; however, our data do not support the hypothesis that bcl-2 staining confers a better prognosis overall, in squamous cell carcinoma, or in an older patient population.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalHuman Pathology
Volume29
Issue number1
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Immunohistochemistry
Staining and Labeling
Adenocarcinoma
Smoking
bcl-2 Genes
Neoplasms
Mutation
Aptitude
Paraffin
Formaldehyde
Disease-Free Survival
Squamous Cell Carcinoma
Cell Survival
Histology
Carcinogenesis
Proteins
Body Mass Index
Clone Cells
History

Keywords

  • Apoptosis
  • Bcl-2
  • Immunohistochemistry
  • Lung carcinoma
  • Non-small cell

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Fleming, M. V., Guinee D.G., J., Chu, W. S., Freedman, A. N., Caporaso, N. E., Bennett, W. P., ... Travis, W. D. (1998). Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Human Pathology, 29(1), 60-64. https://doi.org/10.1016/S0046-8177(98)90391-4

Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. / Fleming, M. V.; Guinee D.G., Jr; Chu, W. S.; Freedman, A. N.; Caporaso, N. E.; Bennett, W. P.; Colby, T. V.; Tazelaar, H.; Abbondanzo, S. L.; Jett, J.; Pairolero, P.; Trastek, V.; Liotta, L. A.; Harris, C. C.; Travis, W. D.

In: Human Pathology, Vol. 29, No. 1, 1998, p. 60-64.

Research output: Contribution to journalArticle

Fleming, MV, Guinee D.G., J, Chu, WS, Freedman, AN, Caporaso, NE, Bennett, WP, Colby, TV, Tazelaar, H, Abbondanzo, SL, Jett, J, Pairolero, P, Trastek, V, Liotta, LA, Harris, CC & Travis, WD 1998, 'Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients', Human Pathology, vol. 29, no. 1, pp. 60-64. https://doi.org/10.1016/S0046-8177(98)90391-4
Fleming MV, Guinee D.G. J, Chu WS, Freedman AN, Caporaso NE, Bennett WP et al. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Human Pathology. 1998;29(1):60-64. https://doi.org/10.1016/S0046-8177(98)90391-4
Fleming, M. V. ; Guinee D.G., Jr ; Chu, W. S. ; Freedman, A. N. ; Caporaso, N. E. ; Bennett, W. P. ; Colby, T. V. ; Tazelaar, H. ; Abbondanzo, S. L. ; Jett, J. ; Pairolero, P. ; Trastek, V. ; Liotta, L. A. ; Harris, C. C. ; Travis, W. D. / Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. In: Human Pathology. 1998 ; Vol. 29, No. 1. pp. 60-64.
@article{02fbf1bb04d64cb5848185946682f08b,
title = "Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients",
abstract = "The bcl-2 gene is implicated in oncogenesis by its ability to prolong cell survival through the inhibition of apoptosis, without increasing cell proliferation. An association between immunohistochemical staining for bcl-2 protein and the histological type and prognosis of non-small cell carcinoma was hypothesized by Pezzella et al. (N Engl J Med 329:690-694, 1993). In a case series, we stained formalin-fixed, paraffin-bedded tumor tissue from 106 surgical non-small cell lung cancer patients with an antibody to bcl-2 protein (DAKO clone 124, Carpinteria, CA). The resulting bcl-2 staining data were evaluated for associations with demographic, histological, immunohistochemical, and genetic features, including p53 mutations. Bcl-2 staining was observed in tumors from 29 of 106 (27{\%}) of subjects, but was significantly less frequent in subjects' adenocarcinoma histology (8 of 55, 14.6{\%}) (P = .007). This finding persisted after adjustment for age, gender, stage, grade, smoking history, and disease-free survival. In univariate analyses, no association was seen with age, weight, body mass index, gender, or pack-years smoking; tumor grade, stage, or patient performance status; p53 or c-erbB2 immunohistochemical staining, or p53 mutations. These data agree with earlier reports that bcl-2 staining is less common in adenocarcinomas; however, our data do not support the hypothesis that bcl-2 staining confers a better prognosis overall, in squamous cell carcinoma, or in an older patient population.",
keywords = "Apoptosis, Bcl-2, Immunohistochemistry, Lung carcinoma, Non-small cell",
author = "Fleming, {M. V.} and {Guinee D.G.}, Jr and Chu, {W. S.} and Freedman, {A. N.} and Caporaso, {N. E.} and Bennett, {W. P.} and Colby, {T. V.} and H. Tazelaar and Abbondanzo, {S. L.} and J. Jett and P. Pairolero and V. Trastek and Liotta, {L. A.} and Harris, {C. C.} and Travis, {W. D.}",
year = "1998",
doi = "10.1016/S0046-8177(98)90391-4",
language = "English (US)",
volume = "29",
pages = "60--64",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients

AU - Fleming, M. V.

AU - Guinee D.G., Jr

AU - Chu, W. S.

AU - Freedman, A. N.

AU - Caporaso, N. E.

AU - Bennett, W. P.

AU - Colby, T. V.

AU - Tazelaar, H.

AU - Abbondanzo, S. L.

AU - Jett, J.

AU - Pairolero, P.

AU - Trastek, V.

AU - Liotta, L. A.

AU - Harris, C. C.

AU - Travis, W. D.

PY - 1998

Y1 - 1998

N2 - The bcl-2 gene is implicated in oncogenesis by its ability to prolong cell survival through the inhibition of apoptosis, without increasing cell proliferation. An association between immunohistochemical staining for bcl-2 protein and the histological type and prognosis of non-small cell carcinoma was hypothesized by Pezzella et al. (N Engl J Med 329:690-694, 1993). In a case series, we stained formalin-fixed, paraffin-bedded tumor tissue from 106 surgical non-small cell lung cancer patients with an antibody to bcl-2 protein (DAKO clone 124, Carpinteria, CA). The resulting bcl-2 staining data were evaluated for associations with demographic, histological, immunohistochemical, and genetic features, including p53 mutations. Bcl-2 staining was observed in tumors from 29 of 106 (27%) of subjects, but was significantly less frequent in subjects' adenocarcinoma histology (8 of 55, 14.6%) (P = .007). This finding persisted after adjustment for age, gender, stage, grade, smoking history, and disease-free survival. In univariate analyses, no association was seen with age, weight, body mass index, gender, or pack-years smoking; tumor grade, stage, or patient performance status; p53 or c-erbB2 immunohistochemical staining, or p53 mutations. These data agree with earlier reports that bcl-2 staining is less common in adenocarcinomas; however, our data do not support the hypothesis that bcl-2 staining confers a better prognosis overall, in squamous cell carcinoma, or in an older patient population.

AB - The bcl-2 gene is implicated in oncogenesis by its ability to prolong cell survival through the inhibition of apoptosis, without increasing cell proliferation. An association between immunohistochemical staining for bcl-2 protein and the histological type and prognosis of non-small cell carcinoma was hypothesized by Pezzella et al. (N Engl J Med 329:690-694, 1993). In a case series, we stained formalin-fixed, paraffin-bedded tumor tissue from 106 surgical non-small cell lung cancer patients with an antibody to bcl-2 protein (DAKO clone 124, Carpinteria, CA). The resulting bcl-2 staining data were evaluated for associations with demographic, histological, immunohistochemical, and genetic features, including p53 mutations. Bcl-2 staining was observed in tumors from 29 of 106 (27%) of subjects, but was significantly less frequent in subjects' adenocarcinoma histology (8 of 55, 14.6%) (P = .007). This finding persisted after adjustment for age, gender, stage, grade, smoking history, and disease-free survival. In univariate analyses, no association was seen with age, weight, body mass index, gender, or pack-years smoking; tumor grade, stage, or patient performance status; p53 or c-erbB2 immunohistochemical staining, or p53 mutations. These data agree with earlier reports that bcl-2 staining is less common in adenocarcinomas; however, our data do not support the hypothesis that bcl-2 staining confers a better prognosis overall, in squamous cell carcinoma, or in an older patient population.

KW - Apoptosis

KW - Bcl-2

KW - Immunohistochemistry

KW - Lung carcinoma

KW - Non-small cell

UR - http://www.scopus.com/inward/record.url?scp=0031964567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031964567&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(98)90391-4

DO - 10.1016/S0046-8177(98)90391-4

M3 - Article

VL - 29

SP - 60

EP - 64

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 1

ER -